Cygenics contract with DOD renewed
Wednesday, 16 February, 2005
Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.
The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.
The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
